At the Extraordinary General Meeting of 2cureX AB (publ), held on 2 July 2020, the general meeting resolved to increase the number of members of the Board to six members. The general meeting also resolved to dismiss Timm Jessen, co-founder of 2cureX, who decided to leave the Board for personal reasons, and to appoint Nils Brünner and Michael Lutz as new board members. Michael Lutz is an experienced international biotech entrepreneur who has spent the last 15 years at executive management positions with several US and European Life Sciences companies which he successfully established or built-up to a successful exit. Michael is currently CEO of HepaRegeniX GmbH (Tübingen, Germany) and also serves on the Strategic & Scientific Advisory Board for Noscendo GmbH. Nils Brünner is medical oncologist with extensive experience both as clinician and as biotech entrepreneur. Nils is a highly recognized scientist with more than 370 scientific papers especially in the field of translational cancer research. Nils is co-founder and CEO of Scandion Oncology A/S where he, through development of a first in class drug candidate against drug resistance in cancer patients, has moved the company to be one of the most successful listed companies at Stockholm Stock Exchange.